According to the latest data from the Hong Kong Stock Exchange, on February 2, JPMorgan increased its holdings in Innovent Bio (01801) by 1,233,667 shares at a price of HK$78.6975 per share. The total transaction value amounted to approximately HK$97.09 million. Following this acquisition, the firm's total shareholding reached about 87.91 million shares, representing a stake of 5.06%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.